240 related articles for article (PubMed ID: 28679689)
1. Two different, mutually exclusively distributed,
Sukhbaatar N; Bachmayr-Heyda A; Auer K; Aust S; Deycmar S; Horvat R; Pils D
Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679689
[TBL] [Abstract][Full Text] [Related]
2. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer.
Auer K; Bachmayr-Heyda A; Aust S; Grunt TW; Pils D
Cancer Lett; 2017 Mar; 388():158-166. PubMed ID: 27940126
[TBL] [Abstract][Full Text] [Related]
3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
4. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
5. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.
Eckert MA; Pan S; Hernandez KM; Loth RM; Andrade J; Volchenboum SL; Faber P; Montag A; Lastra R; Peter ME; Yamada SD; Lengyel E
Cancer Discov; 2016 Dec; 6(12):1342-1351. PubMed ID: 27856443
[TBL] [Abstract][Full Text] [Related]
6. Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.
Singh N; Faruqi A; Kommoss F; McCluggage WG; Trevisan G; Senz J; Lum A; Gilks CB; Anglesio M
Mod Pathol; 2018 Apr; 31(4):652-659. PubMed ID: 29148539
[TBL] [Abstract][Full Text] [Related]
7. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP
J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522
[TBL] [Abstract][Full Text] [Related]
8. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
9. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
[TBL] [Abstract][Full Text] [Related]
10. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.
Zhang S; Dolgalev I; Zhang T; Ran H; Levine DA; Neel BG
Nat Commun; 2019 Nov; 10(1):5367. PubMed ID: 31772167
[TBL] [Abstract][Full Text] [Related]
11. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
[TBL] [Abstract][Full Text] [Related]
13. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
14. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
15. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
Kim HN; Woo HY; DO SI; Kim HS
In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
17. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
18. [Serous genital carcinoma: molecular pathogenesis and the role of tubal fimbria].
Lax S
Pathologe; 2009 Dec; 30 Suppl 2():210-6. PubMed ID: 19859709
[TBL] [Abstract][Full Text] [Related]
19. Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries.
Anglesio MS; O'Neill CJ; Senz J; Gilks CB; McCluggage WG
Histopathology; 2017 Dec; 71(6):1014-1017. PubMed ID: 28746984
[No Abstract] [Full Text] [Related]
20. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome.
Auer K; Bachmayr-Heyda A; Aust S; Sukhbaatar N; Reiner AT; Grimm C; Horvat R; Zeillinger R; Pils D
Oncotarget; 2015 Jul; 6(19):17261-75. PubMed ID: 25991672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
